Global Cancer API Market: Industry Analysis and forecast 2019 – 2027: By Degib , Tinib , Rafenib, Parib,and Region.

Global Cancer API Market size is expected to grow at 6.42% throughout the forecast period, reaching nearly US$ 20.5 Bn. by 2027. To know about the Research Methodology :- Request Free Sample Report The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis. Cancer API (Active Pharmaceutical Ingredient) is the ingredient in medicinal drug use for cancer. The cancer is disordered and unregulated cell development. As per the WHO, nearly 65% of all cancer deaths occur in developing economies and the number of worldwide cancer deaths is expected to upsurge by 45% from 2007 to 2030 with 7.9 Mn. to 11.5 Mn. deaths influenced by the increase in consumption of unhealthy diet, tobacco use, insufficient physical activity and the harmful use of alcohol in major regions. The cancer API market dynamics are thoroughly studied and explained in the MMR report, which helps to understand emerging market trends, drivers, restraints, opportunities, and challenges at the global and regional level for the cancer API market globally. Such as, growing demand for small molecule drug is one of the initial factors enhancing the growth of the Cancer API market. The small molecule cancer API market is suffering a period of rapid change. Small molecules are pre-dominating the industry of pharmaceutical and account for approximately 80 % of the pharmaceutical sales, signifying their relevance in the upcoming future of pharmaceuticals. Also, small molecules have made major development in the field of cancer treatment. In the global cancer API market main API molecule segments include degib, tinib, rafenib, and parib. The Pfizer Company currently dominates the cancer API market globally with 23.2 % of the entire market share. Pfizer Company has generated exceptional revenue figures because of the sales of cancer drugs like ‘Xalkori,’ ‘Bosulif,’ ‘Inlyta,’ ‘Ibrance,’ and a few others. The Ibrance is the drug which is mainly responsible for fueling Pfizer to the top spot in cancer API market. Also, AbbVie Company has the second-largest cancer API market share globally. AbbVie Company holds 17.7 % of the total market share. The report also offers a brief analysis of the major regions in the Global Cancer API Market, namely, Asia, Europe, North America, South America, and the MEA. Among this, North America accounted for the largest cancer API market share in 2019, with a market value of US$ XX Mn; the regional market is expected to register a CAGR of XX.11% during 2019-2027. This is attributed to the potential rate due to the presence of pharmaceutical key players for new drug discovery using new technology in the USA. As stated by the IFPMA (International Federation of Pharmaceutical Manufacturers and Associations), the United State holds 45 % worldwide market share for pharmaceutical companies with new drug discovery using the API with expenditure has been increased from US$ 461.7 Bn. in 2016. In recent years, major players in the cancer API market have taken several strategic measures, like facility expansions and partnerships. In 2018, Eli Lilly and Company acquired AurKa Pharma and Armo Biosciences in order to develop its cancer portfolio. The MMR reports also cover key developments in the cancer API market as organic and inorganic growth strategies. In 2018, Boehringer Ingelheim Company launched a new production facility for inventive drugs. The facility focuses on manufacturing and development of drugs in tablet form previously launching them worldwide. The objective of the report is to present a comprehensive analysis of the Global Cancer API Marketincluding all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Cancer API Marketdynamics, structure by analyzing the market segments and projects the Global Cancer API Marketsize. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Cancer API Market make the report investor’s guide.

Scope of the Global Cancer API Market: Inquire before buying

Global Cancer API Market, By Degib

• Sonidegib • Vismodegib

Global Cancer API Market, By Tinib

• Ponatinib • Brigatinib

Global Cancer API Market, By Rafenib

• Sorafenib • Regorafenib • Vemurafenib

Global Cancer API Market, By Parib

• Olaparib • Rucaparib • Niraparib

Global Cancer API Market, By Region

• Asia Pacific  India  China  Japan  South Korea  Australia  Indonesia  Malaysia  Vietnam  Rest of Asia • North America  U.S.  Canada • Europe  U.K  Germany  France  Russia  Spain  Italy  Sweden • South America  Mexico  Brazil  Rest of South America • Middle East & Africa  GCC  South Africa  Rest of MEA

Key players operating in the Global Cancer API Market

• Exelixis Inc. • Pfizer Inc. • Eisai Ltd. • Bristol-Myers Squibb • AbbVie Inc. • F. Hoffman La Roche • AstraZeneca PLC • Novartis AG • Bayer AG • Ariad Pharmaceuticals Inc. • Boehringer Ingelheim • Celgene • Eli Lilly & Company • Puma Biotech • TESARO, Inc.
Global Cancer API Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Cancer API Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Cancer API Market Analysis and Forecast 6.1. Cancer API Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Cancer API Market Analysis and Forecast, By Degib 7.1. Introduction and Definition 7.2. Key Findings 7.3. Cancer API Market Value Share Analysis, By Degib 7.4. Cancer API Market Size (US$ Bn) Forecast, By Degib 7.5. Cancer API Market Analysis, By Degib 7.6. Cancer API Market Attractiveness Analysis, By Degib 8. Global Cancer API Market Analysis and Forecast, By Rafenib 8.1. Introduction and Definition 8.2. Key Findings 8.3. Cancer API Market Value Share Analysis, By Rafenib 8.4. Cancer API Market Size (US$ Bn) Forecast, By Rafenib 8.5. Cancer API Market Analysis, By Rafenib 8.6. Cancer API Market Attractiveness Analysis, By Rafenib 9. Global Cancer API Market Analysis and Forecast, By Tinib 9.1. Introduction and Definition 9.2. Key Findings 9.3. Cancer API Market Value Share Analysis, By Tinib 9.4. Cancer API Market Size (US$ Bn) Forecast, By Tinib 9.5. Cancer API Market Analysis, By Tinib 9.6. Cancer API Market Attractiveness Analysis, By Tinib 10. Global Cancer API Market Analysis and Forecast, By Parib 10.1. Introduction and Definition 10.2. Key Findings 10.3. Cancer API Market Value Share Analysis, By Parib 10.4. Cancer API Market Size (US$ Bn) Forecast, By Parib 10.5. Cancer API Market Analysis, By Parib 10.6. Cancer API Market Attractiveness Analysis, By Parib 11. Global Cancer API Market Analysis, by Region 11.1. Cancer API Market Value Share Analysis, by Region 11.2. Cancer API Market Size (US$ Bn) Forecast, by Region 11.3. Cancer API Market Attractiveness Analysis, by Region 12. North America Cancer API Market Analysis 12.1. Key Findings 12.2. North America Cancer API Market Overview 12.3. North America Cancer API Market Value Share Analysis, By Degib 12.4. North America Cancer API Market Forecast, By Degib 12.4.1. Sonidegib 12.4.2. Vismodegib 12.5. North America Cancer API Market Value Share Analysis, By Rafenib 12.6. North America Cancer API Market Forecast, By Rafenib 12.6.1. Sorafenib 12.6.2. Regorafenib 12.6.3. Vemurafenib 12.7. North America Cancer API Market Value Share Analysis, By Tinib 12.8. North America Cancer API Market Forecast, By Tinib 12.8.1. Ponatinib 12.8.2. Brigatinib 12.9. North America Cancer API Market Value Share Analysis, By Parib 12.10. North America Cancer API Market Forecast, By Parib 12.10.1. Olaparib 12.10.2. Rucaparib 12.10.3. Niraparib 12.11. North America Cancer API Market Value Share Analysis, by Country 12.12. North America Cancer API Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Cancer API Market Analysis, by Country 12.14. U.S. Cancer API Market Forecast, By Degib 12.14.1. Sonidegib 12.14.2. Vismodegib 12.15. U.S. Cancer API Market Forecast, By Rafenib 12.15.1. Sorafenib 12.15.2. Regorafenib 12.15.3. Vemurafenib 12.16. U.S. Cancer API Market Forecast, By Tinib 12.16.1. Ponatinib 12.16.2. Brigatinib 12.17. U.S. Cancer API Market Forecast, By Parib 12.17.1. Olaparib 12.17.2. Rucaparib 12.17.3. Niraparib 12.18. Canada Cancer API Market Forecast, By Degib 12.18.1. Sonidegib 12.18.2. Vismodegib 12.19. Canada Cancer API Market Forecast, By Rafenib 12.19.1. Sorafenib 12.19.2. Regorafenib 12.19.3. Vemurafenib 12.20. Canada Cancer API Market Forecast, By Tinib 12.20.1. Ponatinib 12.20.2. Brigatinib 12.21. Canada Cancer API Market Forecast, By Parib 12.21.1. Olaparib 12.21.2. Rucaparib 12.21.3. Niraparib 12.22. North America Cancer API Market Attractiveness Analysis 12.22.1. By Degib 12.22.2. By Rafenib 12.22.3. By Tinib 12.22.4. By Parib 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Cancer API Market Analysis 13.1. Key Findings 13.2. Europe Cancer API Market Overview 13.3. Europe Cancer API Market Value Share Analysis, By Degib 13.4. Europe Cancer API Market Forecast, By Degib 13.4.1. Sonidegib 13.4.2. Vismodegib 13.5. Europe Cancer API Market Value Share Analysis, By Rafenib 13.6. Europe Cancer API Market Forecast, By Rafenib 13.6.1. Sorafenib 13.6.2. Regorafenib 13.6.3. Vemurafenib 13.7. Europe Cancer API Market Value Share Analysis, By Tinib 13.8. Europe Cancer API Market Forecast, By Tinib 13.8.1. Ponatinib 13.8.2. Brigatinib 13.9. Europe Cancer API Market Value Share Analysis, By Parib 13.10. Europe Cancer API Market Forecast, By Parib 13.10.1. Olaparib 13.10.2. Rucaparib 13.10.3. Niraparib 13.11. Europe Cancer API Market Value Share Analysis, by Country 13.12. Europe Cancer API Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Cancer API Market Analysis, by Country 13.14. Germany Cancer API Market Forecast, By Degib 13.14.1. Sonidegib 13.14.2. Vismodegib 13.15. Germany Cancer API Market Forecast, By Rafenib 13.15.1. Sorafenib 13.15.2. Regorafenib 13.15.3. Vemurafenib 13.16. Germany Cancer API Market Forecast, By Tinib 13.16.1. Ponatinib 13.16.2. Brigatinib 13.17. Germany Cancer API Market Forecast, By Parib 13.17.1. Olaparib 13.17.2. Rucaparib 13.17.3. Niraparib 13.18. U.K. Cancer API Market Forecast, By Degib 13.18.1. Sonidegib 13.18.2. Vismodegib 13.19. U.K. Cancer API Market Forecast, By Rafenib 13.19.1. Sorafenib 13.19.2. Regorafenib 13.19.3. Vemurafenib 13.20. U.K. Cancer API Market Forecast, By Tinib 13.20.1. Ponatinib 13.20.2. Brigatinib 13.21. U.K. Cancer API Market Forecast, By Parib 13.21.1. Olaparib 13.21.2. Rucaparib 13.21.3. Niraparib 13.22. France Cancer API Market Forecast, By Degib 13.22.1. Sonidegib 13.22.2. Vismodegib 13.23. France Cancer API Market Forecast, By Rafenib 13.23.1. Sorafenib 13.23.2. Regorafenib 13.23.3. Vemurafenib 13.24. France Cancer API Market Forecast, By Tinib 13.24.1. Ponatinib 13.24.2. Brigatinib 13.25. France Cancer API Market Forecast, By Parib 13.25.1. Olaparib 13.25.2. Rucaparib 13.25.3. Niraparib 13.26. Italy Cancer API Market Forecast, By Degib 13.26.1. Sonidegib 13.26.2. Vismodegib 13.27. Italy Cancer API Market Forecast, By Rafenib 13.27.1. Sorafenib 13.27.2. Regorafenib 13.27.3. Vemurafenib 13.28. Italy Cancer API Market Forecast, By Tinib 13.28.1. Ponatinib 13.28.2. Brigatinib 13.29. Italy Cancer API Market Forecast, By Parib 13.29.1. Olaparib 13.29.2. Rucaparib 13.29.3. Niraparib 13.30. Spain Cancer API Market Forecast, By Degib 13.30.1. Sonidegib 13.30.2. Vismodegib 13.31. Spain Cancer API Market Forecast, By Rafenib 13.31.1. Sorafenib 13.31.2. Regorafenib 13.31.3. Vemurafenib 13.32. Spain Cancer API Market Forecast, By Tinib 13.32.1. Ponatinib 13.32.2. Brigatinib 13.33. Spain Cancer API Market Forecast, By Parib 13.33.1. Olaparib 13.33.2. Rucaparib 13.33.3. Niraparib 13.34. Rest of Europe Cancer API Market Forecast, By Degib 13.34.1. Sonidegib 13.34.2. Vismodegib 13.35. Rest of Europe Cancer API Market Forecast, By Rafenib 13.35.1. Sorafenib 13.35.2. Regorafenib 13.35.3. Vemurafenib 13.36. Rest of Europe Cancer API Market Forecast, By Tinib 13.36.1. Ponatinib 13.36.2. Brigatinib 13.37. Rest Of Europe Cancer API Market Forecast, By Parib 13.37.1. Olaparib 13.37.2. Rucaparib 13.37.3. Niraparib 13.38. Europe Cancer API Market Attractiveness Analysis 13.38.1. By Degib 13.38.2. By Rafenib 13.38.3. By Tinib 13.38.4. By Parib 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Cancer API Market Analysis 14.1. Key Findings 14.2. Asia Pacific Cancer API Market Overview 14.3. Asia Pacific Cancer API Market Value Share Analysis, By Degib 14.4. Asia Pacific Cancer API Market Forecast, By Degib 14.4.1. Sonidegib 14.4.2. Vismodegib 14.5. Asia Pacific Cancer API Market Value Share Analysis, By Rafenib 14.6. Asia Pacific Cancer API Market Forecast, By Rafenib 14.6.1. Sorafenib 14.6.2. Regorafenib 14.6.3. Vemurafenib 14.7. Asia Pacific Cancer API Market Value Share Analysis, By Tinib 14.8. Asia Pacific Cancer API Market Forecast, By Tinib 14.8.1. Ponatinib 14.8.2. Brigatinib 14.9. Asia Pacific Cancer API Market Value Share Analysis, By Parib 14.10. Asia Pacific Cancer API Market Forecast, By Parib 14.10.1. Olaparib 14.10.2. Rucaparib 14.10.3. Niraparib 14.11. Asia Pacific Cancer API Market Value Share Analysis, by Country 14.12. Asia Pacific Cancer API Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Cancer API Market Analysis, by Country 14.14. China Cancer API Market Forecast, By Degib 14.14.1. Sonidegib 14.14.2. Vismodegib 14.15. China Cancer API Market Forecast, By Rafenib 14.15.1. Sorafenib 14.15.2. Regorafenib 14.15.3. Vemurafenib 14.16. China Cancer API Market Forecast, By Tinib 14.16.1. Ponatinib 14.16.2. Brigatinib 14.17. China Cancer API Market Forecast, By Parib 14.17.1. Olaparib 14.17.2. Rucaparib 14.17.3. Niraparib 14.18. India Cancer API Market Forecast, By Degib 14.18.1. Sonidegib 14.18.2. Vismodegib 14.19. India Cancer API Market Forecast, By Rafenib 14.19.1. Sorafenib 14.19.2. Regorafenib 14.19.3. Vemurafenib 14.20. India Cancer API Market Forecast, By Tinib 14.20.1. Ponatinib 14.20.2. Brigatinib 14.21. India Cancer API Market Forecast, By Parib 14.21.1. Olaparib 14.21.2. Rucaparib 14.21.3. Niraparib 14.22. Japan Cancer API Market Forecast, By Degib 14.22.1. Sonidegib 14.22.2. Vismodegib 14.23. Japan Cancer API Market Forecast, By Rafenib 14.23.1. Sorafenib 14.23.2. Regorafenib 14.23.3. Vemurafenib 14.24. Japan Cancer API Market Forecast, By Tinib 14.24.1. Ponatinib 14.24.2. Brigatinib 14.25. Japan Cancer API Market Forecast, By Parib 14.25.1. Olaparib 14.25.2. Rucaparib 14.25.3. Niraparib 14.26. ASEAN Cancer API Market Forecast, By Degib 14.26.1. Sonidegib 14.26.2. Vismodegib 14.27. ASEAN Cancer API Market Forecast, By Rafenib 14.27.1. Sorafenib 14.27.2. Regorafenib 14.27.3. Vemurafenib 14.28. ASEAN Cancer API Market Forecast, By Tinib 14.28.1. Ponatinib 14.28.2. Brigatinib 14.29. ASEAN Cancer API Market Forecast, By Parib 14.29.1. Olaparib 14.29.2. Rucaparib 14.29.3. Niraparib 14.30. Rest of Asia Pacific Cancer API Market Forecast, By Degib 14.30.1. Sonidegib 14.30.2. Vismodegib 14.31. Rest of Asia Pacific Cancer API Market Forecast, By Rafenib 14.31.1. Sorafenib 14.31.2. Regorafenib 14.31.3. Vemurafenib 14.32. Rest of Asia Pacific Cancer API Market Forecast, By Tinib 14.32.1. Ponatinib 14.32.2. Brigatinib 14.33. Rest of Asia Pacific Cancer API Market Forecast, By Parib 14.33.1. Olaparib 14.33.2. Rucaparib 14.33.3. Niraparib 14.34. Asia Pacific Cancer API Market Attractiveness Analysis 14.34.1. By Degib 14.34.2. By Rafenib 14.34.3. By Tinib 14.34.4. By Parib 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Cancer API Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Cancer API Market Overview 15.3. Middle East & Africa Cancer API Market Value Share Analysis, By Degib 15.4. Middle East & Africa Cancer API Market Forecast, By Degib 15.4.1. Sonidegib 15.4.2. Vismodegib 15.5. Middle East & Africa Cancer API Market Value Share Analysis, By Rafenib 15.6. Middle East & Africa Cancer API Market Forecast, By Rafenib 15.6.1. Sorafenib 15.6.2. Regorafenib 15.6.3. Vemurafenib 15.7. Middle East & Africa Cancer API Market Value Share Analysis, By Tinib 15.8. Middle East & Africa Cancer API Market Forecast, By Tinib 15.8.1. Ponatinib 15.8.2. Brigatinib 15.9. Middle East & Africa Cancer API Market Value Share Analysis, By Parib 15.10. Middle East & Africa Cancer API Market Forecast, By Parib 15.10.1. Olaparib 15.10.2. Rucaparib 15.10.3. Niraparib 15.11. Middle East & Africa Cancer API Market Value Share Analysis, by Country 15.12. Middle East & Africa Cancer API Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Cancer API Market Analysis, by Country 15.14. GCC Cancer API Market Forecast, By Degib 15.14.1. Sonidegib 15.14.2. Vismodegib 15.15. GCC Cancer API Market Forecast, By Rafenib 15.15.1. Sorafenib 15.15.2. Regorafenib 15.15.3. Vemurafenib 15.16. GCC Cancer API Market Forecast, By Tinib 15.16.1. Ponatinib 15.16.2. Brigatinib 15.17. GCC Cancer API Market Forecast, By Parib 15.17.1. Olaparib 15.17.2. Rucaparib 15.17.3. Niraparib 15.18. South Africa Cancer API Market Forecast, By Degib 15.18.1. Sonidegib 15.18.2. Vismodegib 15.19. South Africa Cancer API Market Forecast, By Rafenib 15.19.1. Sorafenib 15.19.2. Regorafenib 15.19.3. Vemurafenib 15.20. South Africa Cancer API Market Forecast, By Tinib 15.20.1. Ponatinib 15.20.2. Brigatinib 15.21. South Africa Cancer API Market Forecast, By Parib 15.21.1. Olaparib 15.21.2. Rucaparib 15.21.3. Niraparib 15.22. Rest of Middle East & Africa Cancer API Market Forecast, By Degib 15.22.1. Sonidegib 15.22.2. Vismodegib 15.23. Rest of Middle East & Africa Cancer API Market Forecast, By Rafenib 15.23.1. Sorafenib 15.23.2. Regorafenib 15.23.3. Vemurafenib 15.24. Rest of Middle East & Africa Cancer API Market Forecast, By Tinib 15.24.1. Ponatinib 15.24.2. Brigatinib 15.25. Rest of Middle East & Africa Cancer API Market Forecast, By Parib 15.25.1. Olaparib 15.25.2. Rucaparib 15.25.3. Niraparib 15.26. Middle East & Africa Cancer API Market Attractiveness Analysis 15.26.1. By Degib 15.26.2. By Rafenib 15.26.3. By Tinib 15.26.4. By Parib 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Cancer API Market Analysis 16.1. Key Findings 16.2. South America Cancer API Market Overview 16.3. South America Cancer API Market Value Share Analysis, By Degib 16.4. South America Cancer API Market Forecast, By Degib 16.4.1. Sonidegib 16.4.2. Vismodegib 16.5. South America Cancer API Market Value Share Analysis, By Rafenib 16.6. South America Cancer API Market Forecast, By Rafenib 16.6.1. Sorafenib 16.6.2. Regorafenib 16.6.3. Vemurafenib 16.7. South America Cancer API Market Value Share Analysis, By Tinib 16.8. South America Cancer API Market Forecast, By Tinib 16.8.1. Ponatinib 16.8.2. Brigatinib 16.9. South America Cancer API Market Value Share Analysis, By Parib 16.10. South America Cancer API Market Forecast, By Parib 16.10.1. Olaparib 16.10.2. Rucaparib 16.10.3. Niraparib 16.11. South America Cancer API Market Value Share Analysis, by Country 16.12. South America Cancer API Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Cancer API Market Analysis, by Country 16.14. Brazil Cancer API Market Forecast, By Degib 16.14.1. Sonidegib 16.14.2. Vismodegib 16.15. Brazil Cancer API Market Forecast, By Rafenib 16.15.1. Sorafenib 16.15.2. Regorafenib 16.15.3. Vemurafenib 16.16. Brazil Cancer API Market Forecast, By Tinib 16.16.1. Ponatinib 16.16.2. Brigatinib 16.17. Brazil Cancer API Market Forecast, By Parib 16.17.1. Olaparib 16.17.2. Rucaparib 16.17.3. Niraparib 16.18. Mexico Cancer API Market Forecast, By Degib 16.18.1. Sonidegib 16.18.2. Vismodegib 16.19. Mexico Cancer API Market Forecast, By Rafenib 16.19.1. Sorafenib 16.19.2. Regorafenib 16.19.3. Vemurafenib 16.20. Mexico Cancer API Market Forecast, By Tinib 16.20.1. Ponatinib 16.20.2. Brigatinib 16.21. Mexico Cancer API Market Forecast, By Parib 16.21.1. Olaparib 16.21.2. Rucaparib 16.21.3. Niraparib 16.22. Rest of South America Cancer API Market Forecast, By Degib 16.22.1. Sonidegib 16.22.2. Vismodegib 16.23. Rest of South America Cancer API Market Forecast, By Rafenib 16.23.1. Sorafenib 16.23.2. Regorafenib 16.23.3. Vemurafenib 16.24. Rest of South America Cancer API Market Forecast, By Tinib 16.24.1. Ponatinib 16.24.2. Brigatinib 16.25. Rest of South America Cancer API Market Forecast, By Parib 16.25.1. Olaparib 16.25.2. Rucaparib 16.25.3. Niraparib 16.26. South America Cancer API Market Attractiveness Analysis 16.26.1. By Degib 16.26.2. By Rafenib 16.26.3. By Tinib 16.26.4. By Parib 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and BackwardIntegration 17.3. Company Profiles: Key Players 17.3.1. Exelixis Inc. 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Development Footprint 17.3.2. Pfizer Inc. 17.3.3. Eisai Ltd. 17.3.4. Bristol-Myers Squibb 17.3.5. AbbVie Inc. 17.3.6. F. Hoffman La Roche 17.3.7. AstraZeneca PLC 17.3.8. Novartis AG 17.3.9. Bayer AG 17.3.10. Ariad Pharmaceuticals Inc. 17.3.11. Boehringer Ingelheim 17.3.12. Celgene 17.3.13. Eli Lilly & Company 17.3.14. Puma Biotech 17.3.15. TESARO, Inc. 18. Primary Key Insights

About This Report

Report ID 70112
Category Healthcare
Published Date August2020
Updated Date
Contact Us